Jasper Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2026 Annual Meeting of Stockholders held by Jasper Therapeutics, Inc. on July 31, 2026. The company is an emerging growth company incorporated in Delaware with its principal executive offices in Redwood City, California.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
Stockholders represented approximately 75% of the 28,009,802 shares issued and outstanding as of the June 5, 2026 record date. The following proposals were approved:
- Proposal 1 (Election of Directors): Two Class II directors, Judith Shizuru, M.D., Ph.D., and Tom Wiggans, were elected to serve until the 2029 annual meeting. Both nominees received over 9.2 million votes in favor.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The proposal received 20,635,404 votes for.
- Proposal 3 (Executive Compensation): Stockholders approved, on an advisory basis, the compensation of the named executive officers. The proposal received 9,016,797 votes for.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on financial outlook, specific risks, contingencies, or unusual items. The document serves solely to disclose the outcomes of the annual meeting.
Key Facts for Investor Verification
- Verify the definitive proxy statement filed on June 15, 2026, for detailed background on the director nominees and executive compensation.
- Confirm the total number of shares outstanding (28,009,802) as of the June 5, 2026 record date.
- Note the significant number of broker non-votes (11,427,758) recorded for the director election and executive compensation proposals.
- Confirm the term of the newly elected directors extends through the 2029 annual meeting.